Ajinomoto Co., Inc. has entered into a definitive agreement to acquire Forge Biologics, a manufacturer of genetic medicines, for $620 million in cash.    Forge is a viral vector and plasmid CDMO and clinical-stage therapeutics company. All development and manufacturing is done at Forge’s 200,000 sq.-ft. custom-designed cGMP facility in Columbus, OH, where the business has more than 300 employees.    “We’re excited to join Ajinomoto Co. to continue to expand our global business of helping inn...